Objective-Epidemiological studies link higher serum phosphate and the phosphatonin fibroblast growth factor 23 with cardiovascular events and atheroma, and they link lower serum phosphate with insulin resistance and the metabolic syndrome. We investigated whether manipulating dietary phosphate influences atherogenesis or insulin sensitivity in mice. Methods and Results-Apolipoprotein E knockout mice were fed an atherogenic diet with low (0.2%), standard (0.6%), or high (1.6%) phosphate content. Serum phosphate and fibroblast growth factor 23 significantly increased with increasing dietary phosphate intake, but lipid profile and blood pressure were unaffected. After 20 weeks, mice on the higher phosphate diet had significantly more atheroma at the aortic sinus (42Ϯ1.9% versus 30Ϯ1.5% for high versus low phosphate, PϽ0.01). Compared with standard and high-phosphate diet groups, mice on a low-phosphate diet had more adipose tissue and a 4-fold increase in insulin resistance measured by homeostatic model assessment (43.7Ϯ9.3 versus 8.9Ϯ0.7 for low versus high phosphate, PϽ0.005). Conclusion-A high-phosphate diet accelerates atherogenesis in apolipoprotein E Ϫ/Ϫ mice, whereas low phosphate intake induces insulin resistance. These data indicate for the first time that controlling dietary phosphate intake may influence development of both atherosclerosis and the metabolic syndrome. (Arterioscler Thromb Vasc Biol. 2011;31:1988-1990.)
I n human observational studies, higher serum phosphate levels within the normal range have been associated with a marked increase in cardiovascular events. 1, 2 Adverse outcomes linked to such elevations in serum phosphate include myocardial infarction, 2 coronary artery disease, 3 coronary calcification, 4 and cardiovascular mortality. 2 These associations are observed despite adjusting for recognized risk factors. The phosphate-regulatory hormone fibroblast growth factor 23, which increases in response to increased dietary phosphate intake, has similarly been linked to cardiovascular disease. 5 Conversely, lower serum phosphate has been associated with insulin resistance and the metabolic syndrome, 6 which are themselves risk factors for atherosclerosis.
See accompanying article on page 1951
It is unknown whether these observations reflect causal relationships between phosphate levels within the normal range and cardiovascular disease. Demonstration of a causal relationship would have profound public health implications, because Western diets are high in bioavailable phosphate as a consequence of phosphate-containing additives and high animal protein content. 7
Methods
An expanded Methods section is given in the supplemental material, available online at http://atvb.ahajournals.org.
Animals and Diets
Eight-week-old male apolipoprotein E knockout mice were randomly assigned to atherogenic diets (21% fat, 0.2% cholesterol, 0.03% cholate) with low (0.2%), standard (0.6%), or high (1.6%) phosphate content. Groups were fed the test diets for 12 weeks (group 1, nϭ14) and 20 weeks (group 2, nϭ19, 5 to 8 per diet) before euthanization under pentobarbital anesthesia for cardiac puncture and tissue collection.
Atheroma Analysis
Atheroma burden was quantified using morphometric analysis in cross-sections through the aortic sinus at the level of the aortic valves and stained with Alcian Blue/elastic van Gieson. Calcification was assessed by von Kossa stain, and smooth muscle cell and macrophage content was assessed by immunostaining.
Statistical Methods
Data are presented as meanϮSEM. Groups were compared by 1-way ANOVA with Tukey post hoc analysis.
Results

Increased Dietary Phosphate Intake Accelerates Atherogenesis in Apolipoprotein E ؊/؊ Mice
Increased dietary phosphate intake caused a significant increase in serum phosphate, parathyroid hormone, and fibroblast growth factor 23 and a small but significant reduction in serum calcium ( Figure 1 and Table) . The low-phosphate diet increased weight gain, but there were no significant differences in blood pressures, lipid profile, urea, or total chow consumption (see supplemental material).
Increased dietary phosphate intake had no effect on aortic sinus atheroma at 12 weeks but was associated with significantly more atheroma at 20 weeks ( Figure 1A and 1B): 30Ϯ2%, 33Ϯ2%, and 42Ϯ2% for low-, standard-, and high-phosphate groups, respectively (PϽ0.01 for low versus high), corresponding to a 40% increase in atheroma burden for the high versus low dietary phosphate groups. Calcification was absent by von Kossa staining, and lesions did not differ in vascular smooth muscle cell or macrophage content (data not shown).
Low Dietary Phosphate Intake Increases Insulin Resistance, Adiposity, and Hepatic Steatosis
Epididymal fat pad mass was significantly greater in the low versus high dietary phosphate group (84Ϯ23 mg versus 19Ϯ8 mg, PϽ0.05, Figure 2A ). Insulin resistance measured by homeostatic model assessment was increased 4-fold on a low-phosphate diet in comparison with other dietary groups (43.7Ϯ9.3 versus 11.1Ϯ0.8 and 8.9Ϯ0.7, PϽ0.005, Figure  2B and 2D). This was not accounted for by adiponectin, which did not differ between low and standard dietary phosphate groups (Figure 2E ). Hepatic steatosis was induced in the low-phosphate group and was accompanied by greater liver weight and alanine transaminase ( Figure 2F to 2I ).
Discussion
This is the first interventional study demonstrating an atherogenic effect of dietary phosphate supplementation. In keeping with human observational data, atheroma burden was least in the low-phosphate group despite the induction of insulin resistance. Modulation of components of the phosphate homeostatic axis (fibroblast growth factor 23, parathyroid hormone, calcitriol) could be responsible for this accelerated atherogenesis. Phosphate itself has been implicated as an endothelial toxin, and postprandial peaks may lead to accumulation of endothelial damage that over time predisposes to atherosclerosis. 8 Low dietary phosphate intake has not previously been demonstrated to induce insulin resistance, adiposity, or steatosis. Xie et al reported increased plasma glucose after phosphate deprivation in rats, attributed to increased hepatic glucose export. 9 We observed induction of insulin resistance measured by homeostatic model assessment, in keeping with the observational population data. 6 This may be a consequence of increased adiposity, impaired phosphometabolite synthesis, or another mechanism.
In summary, we have demonstrated causal relationships between increased dietary phosphate and atherosclerosis, without significant alteration of lipid levels, and between low dietary phosphate and insulin resistance. Given the substantial increases in cardiovascular disease associated observationally with higher phosphate and the massive global burden 
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